pubmed-article:19216081 | rdf:type | pubmed:Citation | lld:pubmed |
pubmed-article:19216081 | lifeskim:mentions | umls-concept:C0035647 | lld:lifeskim |
pubmed-article:19216081 | lifeskim:mentions | umls-concept:C0006118 | lld:lifeskim |
pubmed-article:19216081 | lifeskim:mentions | umls-concept:C0001128 | lld:lifeskim |
pubmed-article:19216081 | lifeskim:mentions | umls-concept:C0220781 | lld:lifeskim |
pubmed-article:19216081 | lifeskim:mentions | umls-concept:C0220825 | lld:lifeskim |
pubmed-article:19216081 | lifeskim:mentions | umls-concept:C1883254 | lld:lifeskim |
pubmed-article:19216081 | lifeskim:mentions | umls-concept:C0032743 | lld:lifeskim |
pubmed-article:19216081 | lifeskim:mentions | umls-concept:C0205460 | lld:lifeskim |
pubmed-article:19216081 | lifeskim:mentions | umls-concept:C1512628 | lld:lifeskim |
pubmed-article:19216081 | pubmed:issue | 5 | lld:pubmed |
pubmed-article:19216081 | pubmed:dateCreated | 2009-3-2 | lld:pubmed |
pubmed-article:19216081 | pubmed:abstractText | Amino acid syn-1-amino-3-fluoro-cyclobutyl-1-carboxylic acid (syn-FACBC) 12, the isomer of anti-FACBC, has been selectively synthesized and [(18)F] radiofluorinated in 52% decay-corrected yield using no-carrier-added [(18)F]fluoride. The key step in the synthesis of the desired isomer involved stereoselective reduction using lithium alkylborohydride/zinc chloride, which improved the ratio of anti-alcohol to syn-alcohol from 17:83 to 97:3. syn-FACBC 12 entered rat 9L gliosarcoma cells primarily via L-type amino acid transport in vitro with high uptake of 16% injected dose per 5 x 10(5) cells. Biodistribution studies in rats with 9L gliosarcoma brain tumors demonstrated high tumor to brain ratio of 12:1 at 30 min post injection. In this model, amino acid syn-[(18)F]FACBC 12 is a promising metabolically based radiotracer for positron emission tomography brain tumor imaging. | lld:pubmed |
pubmed-article:19216081 | pubmed:language | eng | lld:pubmed |
pubmed-article:19216081 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:19216081 | pubmed:citationSubset | IM | lld:pubmed |
pubmed-article:19216081 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:19216081 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:19216081 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:19216081 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:19216081 | pubmed:status | MEDLINE | lld:pubmed |
pubmed-article:19216081 | pubmed:month | Mar | lld:pubmed |
pubmed-article:19216081 | pubmed:issn | 1464-3391 | lld:pubmed |
pubmed-article:19216081 | pubmed:author | pubmed-author:OlsonJeffrey... | lld:pubmed |
pubmed-article:19216081 | pubmed:author | pubmed-author:YuWeipingW | lld:pubmed |
pubmed-article:19216081 | pubmed:author | pubmed-author:GoodmanMark... | lld:pubmed |
pubmed-article:19216081 | pubmed:author | pubmed-author:CampVernon... | lld:pubmed |
pubmed-article:19216081 | pubmed:author | pubmed-author:WilliamsLarry... | lld:pubmed |
pubmed-article:19216081 | pubmed:author | pubmed-author:MalveauxEugen... | lld:pubmed |
pubmed-article:19216081 | pubmed:issnType | Electronic | lld:pubmed |
pubmed-article:19216081 | pubmed:day | 1 | lld:pubmed |
pubmed-article:19216081 | pubmed:volume | 17 | lld:pubmed |
pubmed-article:19216081 | pubmed:owner | NLM | lld:pubmed |
pubmed-article:19216081 | pubmed:authorsComplete | Y | lld:pubmed |
pubmed-article:19216081 | pubmed:pagination | 1982-90 | lld:pubmed |
pubmed-article:19216081 | pubmed:meshHeading | pubmed-meshheading:19216081... | lld:pubmed |
pubmed-article:19216081 | pubmed:meshHeading | pubmed-meshheading:19216081... | lld:pubmed |
pubmed-article:19216081 | pubmed:meshHeading | pubmed-meshheading:19216081... | lld:pubmed |
pubmed-article:19216081 | pubmed:meshHeading | pubmed-meshheading:19216081... | lld:pubmed |
pubmed-article:19216081 | pubmed:meshHeading | pubmed-meshheading:19216081... | lld:pubmed |
pubmed-article:19216081 | pubmed:meshHeading | pubmed-meshheading:19216081... | lld:pubmed |
pubmed-article:19216081 | pubmed:meshHeading | pubmed-meshheading:19216081... | lld:pubmed |
pubmed-article:19216081 | pubmed:meshHeading | pubmed-meshheading:19216081... | lld:pubmed |
pubmed-article:19216081 | pubmed:meshHeading | pubmed-meshheading:19216081... | lld:pubmed |
pubmed-article:19216081 | pubmed:meshHeading | pubmed-meshheading:19216081... | lld:pubmed |
pubmed-article:19216081 | pubmed:meshHeading | pubmed-meshheading:19216081... | lld:pubmed |
pubmed-article:19216081 | pubmed:year | 2009 | lld:pubmed |
pubmed-article:19216081 | pubmed:articleTitle | Stereoselective synthesis and biological evaluation of syn-1-amino-3-[18F]fluorocyclobutyl-1-carboxylic acid as a potential positron emission tomography brain tumor imaging agent. | lld:pubmed |
pubmed-article:19216081 | pubmed:affiliation | Department of Radiology, School of Medicine, Emory University, Atlanta, GA 30322, USA. | lld:pubmed |
pubmed-article:19216081 | pubmed:publicationType | Journal Article | lld:pubmed |
pubmed-article:19216081 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
http://linkedlifedata.com/r... | http://linkedlifedata.com/r... | pubmed-article:19216081 | lld:chembl |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:19216081 | lld:pubmed |